Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Nuvation Bio Inc.

    NYSE: NUVB · Real-Time Price · USD
    2.89
    0.14 (5.09%)
    At close: Aug 18, 2025, 3:59 PM
    2.93
    1.38%
    Pre-market: Aug 19, 2025, 06:58 AM EDT
    5.09%
    Bid 2.92
    Market Cap 989.17M
    Revenue (ttm) 14.36M
    Net Income (ttm) -202.9M
    EPS (ttm) -0.38
    PE Ratio (ttm) -7.61
    Forward PE -3.89
    Analyst Buy
    Ask 2.94
    Volume 4,720,190
    Avg. Volume (20D) 6,343,732
    Open 2.76
    Previous Close 2.75
    Day's Range 2.72 - 2.92
    52-Week Range 1.54 - 3.46
    Beta 1.35

    About NUVB

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol NUVB
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for NUVB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Nuvation Bio Inc. is scheduled to release its earnings on Nov 5, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    7 months ago
    +14.44%
    Nuvation Bio shares are trading higher after RBC C... Unlock content with Pro Subscription
    news image

    1 week ago · zacks.com

    Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates

    Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.17 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.15 per share a year ago.

    news image

    1 week ago · businesswire.com

    Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

    NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today reported financial results for the second quart...

    news image

    3 weeks ago · businesswire.com

    Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

    NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference ...

    news image

    1 month ago · zacks.com

    All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy

    Nuvation Bio (NUVB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    news image

    1 month ago · businesswire.com

    Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers

    NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that taletrectinib (IBTROZ...

    news image

    2 months ago · reuters.com

    US FDA approves Nuvation Bio's lung cancer therapy

    The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's therapy for patients with a type of lung cancer.

    news image

    2 months ago · businesswire.com

    U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

    NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Dru...

    news image

    2 months ago · https://www.defenseworld.net

    UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $925,000 Holdings in Nuvation Bio Inc. (NYSE:NUVB)

    UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Nuvation Bio Inc. (NYSE:NUVB – Free Report) by 54.2% in the 4th quarter, according to the company in i...

    news image

    2 months ago · businesswire.com

    Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting

    NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that additional results fr...

    Add to Watchlist